Bandari RP - Search Results

1

Matched-pair, ⁸⁶Y/⁹⁰Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.

Bandara N, Stott Reynolds TJ, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ. Bandara N, et al. Among authors: bandari rp. Nucl Med Biol. 2018 Jul-Aug;62-63:71-77. doi: 10.1016/j.nucmedbio.2018.06.001. Epub 2018 Jun 8. Nucl Med Biol. 2018. PMID: 29929115 Free PMC article.

2

A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu L, Miao Y, Reynolds TS, Smith CJ. Durkan K, et al. Among authors: bandari rp. Nucl Med Biol. 2014 Feb;41(2):133-9. doi: 10.1016/j.nucmedbio.2013.11.006. Epub 2013 Nov 28. Nucl Med Biol. 2014. PMID: 24480266 Free PMC article.

3

Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ. Bandari RP, et al. Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001. Epub 2014 Jan 10. Nucl Med Biol. 2014. PMID: 24508213 Free PMC article.

4

Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy.

Reynolds TS, Bandari RP, Jiang Z, Smith CJ. Reynolds TS, et al. Among authors: bandari rp. Curr Radiopharm. 2016;9(1):33-43. doi: 10.2174/1874471008666150313112922. Curr Radiopharm. 2016. PMID: 25771366 Review.

5

Design, Synthesis, and in Vitro and in Vivo Evaluation of High Affinity and Specificity Near-Infrared Fluorescent Bombesin Antagonists for Tumor Imaging.

Xu H, Bandari RP, Lee L, Li R, Yu P, Smith CJ, Ma L. Xu H, et al. Among authors: bandari rp. J Med Chem. 2018 Sep 13;61(17):7657-7670. doi: 10.1021/acs.jmedchem.8b00614. Epub 2018 Aug 27. J Med Chem. 2018. PMID: 30111088

6

Development and Preclinical Evaluation of ^99mTc- and ¹⁸⁶Re-Labeled NOTA and NODAGA Bioconjugates Demonstrating Matched Pair Targeting of GRPR-Expressing Tumors.

Makris G, Bandari RP, Kuchuk M, Jurisson SS, Smith CJ, Hennkens HM. Makris G, et al. Among authors: bandari rp. Mol Imaging Biol. 2021 Feb;23(1):52-61. doi: 10.1007/s11307-020-01537-1. Epub 2020 Sep 4. Mol Imaging Biol. 2021. PMID: 32886303

7

Preclinical Evaluation of Novel ⁶⁴Cu-Labeled Gastrin-Releasing Peptide Receptor Bioconjugates for PET Imaging of Prostate Cancer.

Makris G, Shegani A, Kankanamalage PHA, Kuchuk M, Bandari RP, Smith CJ, Hennkens HM. Makris G, et al. Among authors: bandari rp. Bioconjug Chem. 2021 Jul 21;32(7):1290-1297. doi: 10.1021/acs.bioconjchem.0c00656. Epub 2021 Jan 12. Bioconjug Chem. 2021. PMID: 33434428

8

Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA.

Bandari RP, Carmack TL, Malhotra A, Watkinson L, Fergason Cantrell EA, Lewis MR, Smith CJ. Bandari RP, et al. J Med Chem. 2021 Feb 25;64(4):2151-2166. doi: 10.1021/acs.jmedchem.0c01785. Epub 2021 Feb 3. J Med Chem. 2021. PMID: 33534560

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page